Compare Mondaycom Ltd (MNDY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs ResMed Inc. — how do they compare? Mondaycom Ltd trades at $88.96 (market cap $3.76B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 8.5× Mondaycom Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and ResMed Inc. for 51 Days on average.
| MNDY | RMD | |
|---|---|---|
Market Cap | $3.76B | $31.89B |
Volume | 836,200 | 618,314 |
Sector | Technology | Health |
52-Week High | $205.24 | $277.88 |
52-Week Low | $58.81 | $182.82 |
Typical Hold Time | 16 Days | 51 Days |
Enterprise Value | $2.92B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $88.91, up 6.47% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth to $1.23B in 2025, net income of $118.74M, and consistent earnings beats. Recent news highlights AI integration at Elevate '26 conference and inclusion in growth stock lists. Analyst consensus remains strongly bullish with 17 buy ratings and $108.64 price target.
Outlook remains positive given strong enterprise client growth and AI adoption, though elevated valuation ratios (P/E 37.69) and competitive pressures from Meta's enterprise push present risks. The stock offers growth potential but requires monitoring of profit margin sustainability and market volatility.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
